Running Point Capital Advisors’s AbbVie ABBV Stock Holding History

Running Point Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$755K	Sell	3,306 -34	-1%	-$7.75K	0.21%	68
2025 Q3	$773K	Sell	3,340 -561	-14%	-$114K	0.21%	65
2025 Q2	$724K	Sell	3,901 -90	-2%	-$16.7K	0.2%	65
2025 Q1	$836K	Buy	3,991 +601	+18%	+$117K	0.27%	55
2024 Q4	$602K	Hold	3,390	–	–	0.21%	60
2024 Q3	$669K	Buy	3,390 +2	+0.1%	+$373	0.26%	52
2024 Q2	$581K	Hold	3,388	–	–	0.24%	55
2024 Q1	$617K	Buy	+3,388	New	+$584K	0.28%	51

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Running Point Capital Advisors's ABBV Position: Q4 2025 in Review

Running Point Capital Advisors reduced its AbbVie (ABBV) stake by 1% in Q4 2025, selling an estimated $7.75K and leaving 3,306 shares worth $755K. The position accounts for 0.21% of the portfolio, ranked #68.

Running Point Capital Advisors first reported a position in ABBV in Q1 2024 and has held it in 8 quarters since. The position peaked at $836K in Q1 2025. 4,145 funds tracked by Wall St. Rank hold ABBV as of Q4 2025.

Running Point Capital Advisors held 3,306 shares of AbbVie worth $755K as of Q4 2025.
Running Point Capital Advisors sold 34 AbbVie shares in Q4 2025, an estimated $7.75K.
AbbVie made up 0.21% of Running Point Capital Advisors's portfolio in Q4 2025, its #68 holding.
Running Point Capital Advisors first reported a position in AbbVie in Q1 2024 and has held it in 8 quarters since.
Running Point Capital Advisors's AbbVie position peaked at $836K in Q1 2025.
4,145 funds tracked by Wall St. Rank held AbbVie as of Q4 2025.

Based on Running Point Capital Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.